ClinicalTrials.gg
Not yet recruitingNCT07940400ICEBERG-PCUpdated Nov 16, 2026

Integrated Clinical Evaluation of Biomarkers, Radiogenomics, and Genomics in Prostate Cancer

An observational study in Prostate Cancer, sponsored by Wake Forest University Health Sciences. Not yet recruiting at 1 site in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Wake Forest University Health Sciences · Observational

Updated Nov 16, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
5,000
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 30 studies in Prostatic Neoplasms by Wake Forest University Health Sciences — 2 open to participants now, 3 under way, none of them phase 3. Prostatic Neoplasms · Wake Forest University Health Sciences.

Started
2026
the only one that year
Observational
8 of 30
1 open now
Registered
30th of 30
by date

Among the 30 studies in Prostatic Neoplasms by Wake Forest University Health Sciences, this one is the only one that started in 2026, is one of 8 observational ones, and was the 30th registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,579 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

2 of the 30 studies in Prostatic Neoplasms by Wake Forest University Health Sciences are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 1,228 Prostatic Neoplasms studies recruiting now, 927 (75%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Prostatic Neoplasms by Wake Forest University Health Sciences, or all of them as a file.
02

Study summary

Management of prostate cancer increasingly integrates conventional clinicopathologic risk factors with multiparametric magnetic resonance imaging (mpMRI), targeted and systematic biopsy, molecular imaging, and selected tissue-based genomic biomarkers. Contemporary guidelines emphasize risk-adapted shared decision-making and allow selective use of tissue-based genomic biomarkers when additional risk stratification may alter management discussions.

Read the detailed description

The central rationale is to create a source-controlled, longitudinal prostate cancer outcomes cohort in which routine-care genomics, PSMA PET, mpMRI, MRI/ultrasound fusion biopsy, pathology, treatment, and functional outcomes can be analyzed together. The historical component will provide a background population for understanding treatment patterns and outcomes when Decipher® and/or PSMA PET were not obtained. It will not be treated as a formal randomized or concurrent comparator arm. This study is designed to observe that real-world clinical process without assigning testing, imaging, or treatment.

03

Conditions studied

  • Prostate Cancer

Browse trials for

Keywords

  • Prostatectomy
  • Biopsy
  • Tumor characteristics
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Diagnosis of prostate cancer

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years.
  • Diagnosis of prostate cancer documented in the institutional medical record. Prostate adenocarcinoma will constitute the principal analytic population, while other prostate cancer histology's may be retained for descriptive background analyses when .
  • Evaluation, diagnosis, treatment, or follow-up within or beyond Advocate Health Wake Forest Baptist / Wake Forest University School of Medicine and availability of sufficient clinical information for at least one study objective.
  • For the prospective component, first ascertainment after protocol activation will be conducted through routine clinical records or institutional clinical data systems.
  • For the historical background component, available institutional records predating protocol activation will be used to characterize prostate cancer presentation, management, and outcomes

Exclusion criteria

Exclusion Criteria:

  • Insufficient clinical information to establish the relevant diagnosis, treatment, or outcome for a proposed analysis.
  • Records that cannot be used under applicable institutional privacy, data-governance, or IRB requirements.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
5,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • Patients been diagnosed with the prostate cancer

    To determine how clinically obtained tumor genomic and transcriptomic features, phenotype, real-world treatment selection, and longitudinal oncologic outcomes

    Behavioral: The central rationale is to create a source-controlled, longitudinal prostate cancer outcomes cohort in which routine-care genomics, PSMA PET, mpMRI, MRI/ultrasound fusion biopsy, pathology, treatment

Interventions

  • BehavioralThe central rationale is to create a source-controlled, longitudinal prostate cancer outcomes cohort in which routine-care genomics, PSMA PET, mpMRI, MRI/ultrasound fusion biopsy, pathology, treatment

    This study involves no study specific intervention

06

What researchers measure

Primary outcomes

  1. Prostate-Specific Membrane Antigen (PSMA) PET disease extent

    Prostate-Specific Membrane Antigen (PSMA) PET disease extent among patients with clinically obtained Decipher® and PSMA PET, classified as localized versus nonlocalized disease using available molecular-imaging staging data.

    Time frame: up to 5 years

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Dec 2026; primary completion for Dec 2031, 60 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 9, 2026
First posted
Nov 16, 2026
StartEst.
Dec 2026
Primary completionEst.
Dec 2031
CompletionEst.
Dec 2032
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07940400
Responsible party
Sponsor
First posted
Nov 16, 2026
Start date
Dec 2026 (estimated)
Primary completion
Dec 2031 (estimated)
Completion
Dec 2032 (estimated)
Last update
Nov 16, 2026

Study contacts

Sachin Vyas, MS,PhD
Contact
Sachin.vyas@advocatehealth.org
336-713-4098
Thomas Polascik, MD
principal investigator · Wake Forest University Health Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion